Saltar al contenido
Merck

SML0141

Sigma-Aldrich

Trilostane

≥98% (HPLC)

Sinónimos:

(4α,5α,17β)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C20H27NO3
Número de CAS:
Peso molecular:
329.43
Número CE:
Número MDL:
Código UNSPSC:
51111800
ID de la sustancia en PubChem:
NACRES:
NA.77

Análisis

≥98% (HPLC)

formulario

powder

color

white to tan

solubilidad

DMSO: ≥17 mg/mL

temp. de almacenamiento

2-8°C

cadena SMILES

C[C@]12CC[C@H]3[C@@H](CC[C@@]45O[C@@H]4C(O)=C(C[C@]35C)C#N)[C@@H]1CC[C@@H]2O

InChI

1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1

Clave InChI

KVJXBPDAXMEYOA-CXANFOAXSA-N

Información sobre el gen

human ... HSD3B2(3284)

Descripción general

Trilostane inhibits the production of adrenal steroids, such as cortisol and aldosterone. It is used to treat aldosteronism.

Aplicación

Trilostane has been used to evaluate its capability to regulate the sex-dependent differences in the lipopolysaccharide (LPS)-induced inflammatory responses of astrocytes.
Trilostane was used to inhibit the activity of 3β-hydroxysteroid dehydrogenase in mouse ovary.

Acciones bioquímicas o fisiológicas

Trilostane is an inhibitor of 3 β-hydroxysteroid dehydrogenase (3-β-HSD or delta 5-delta 4-isomerase), an essential enzyme for the biosynthesis of all classes of hormonal steroids. It has been used in the treatment of Cushing′s syndrome for stopping the production of cortisol, and is currently approved for dogs in the US, but is still a human drug in the UK and other countries. It is being investigated as a possible treatment for both breast cancer and prostate cancer to prevent the synthesis of estrogens and androgens from endogenous precursors. It has also been used to inhibit endogenous production of progesterone in research studies.

Características y beneficios

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictogramas

Health hazardExclamation mark

Palabra de señalización

Warning

Frases de peligro

Clasificaciones de peligro

Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Nyssa J Reine
Clinical techniques in small animal practice, 22(1), 18-25 (2007-06-05)
Pituitary-dependent hyperadrenocorticism is a common endocrine disorder in dogs in the United States. Once a diagnosis is established, a decision must be made whether or not to pursue treatment, and if so, which medication to use. Historically, mitotane (Lysodren, o,p'-DDD
P M Y Smets et al.
Journal of veterinary internal medicine, 26(3), 565-574 (2012-04-03)
Systemic hypertension and proteinuria are frequent complications in dogs with Cushing's syndrome and do not always resolve after treatment of hypercortisolism. Therefore, dogs with Cushing's syndrome may be at risk for renal dysfunction before and after treatment. To assess renal
Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism
Neiger R , et al.
The Veterinary Record, 150(26), 799-803 (2002)
Edward C Feldman
Journal of the American Veterinary Medical Association, 238(11), 1441-1451 (2011-06-02)
To evaluate effectiveness and incidence of adverse reactions to twice-daily lower-dose oral administration of trilostane in the treatment of dogs with naturally occurring hyperadrenocorticism (NOH). Clinical trial. 47 dogs with NOH. 47 dogs were treated orally with trilostane (0.21 to
K-D Cho et al.
Journal of veterinary internal medicine, 27(1), 91-98 (2012-11-22)
Trilostane is commonly used to treat pituitary-dependent hyperadrenocorticism (PDH) in dogs. There are differing opinions regarding the dose and frequency of trilostane administration in dogs with PDH. To compare the efficacy of 2 trilostane protocols in the treatment of dogs

Artículos

We offers many products related to Nuclear Receptors (Steroids) for your research needs.

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico